Update shared on24 Sep 2025
Fair value Increased 0.59%McKesson’s fair value saw only a marginal increase as analyst expectations for both revenue growth and net profit margin remained virtually unchanged, with the target price moving slightly from $788.57 to $793.21.
What's in the News
- Playhouse MD™, a pediatric healthcare brand, has entered a strategic distribution alliance with McKesson Medical-Surgical, making its products available nationwide and expanding McKesson's portfolio in pediatric care.
- McKesson repurchased 800,000 shares for $560.16 million in the recent quarter, bringing total buybacks to 62 million shares for $16.95 billion under the current program.
- The Board of Directors increased the quarterly dividend by 15% to $0.82 per share.
- McKesson was dropped from the Russell 1000 Defensive, Russell 1000 Value-Defensive, and Russell 1000 Growth-Defensive indexes.
Valuation Changes
Summary of Valuation Changes for McKesson
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $788.57 to $793.21.
- The Consensus Revenue Growth forecasts for McKesson remained effectively unchanged, moving only marginally from 8.2% per annum to 8.4% per annum.
- The Net Profit Margin for McKesson remained effectively unchanged, moving only marginally from 1.11% to 1.13%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.